

2nd International Conference on
VETERINARY AND ANIMAL SCIENCE
&
Annual Summit on **PATHOLOGY**

April 17 -18, 2019 | Tokyo, Japan

Inhibition of β -site amyloid precursor protein cleaving enzyme 1 and cholinesterases by pterosins via specific structure-activity relationship with a strong BBB permeability

Gil Hong Park¹, Susoma Jannat¹, Anand Balupuri², Md Yousof Ali¹, Seong Su Hong³, Chun Whan Choi³, Yun-Hyeok Choi³, Jin-Mo Ku³, Woo Jung Kim³, Jae Yoon Leem⁴, Ju Eun Kim⁴, Abinash Chandra Shrestha⁴, Ha Neul Ham⁴, Kee-Ho Lee⁵, Dong Min Kim⁶ and Nam Sook Kang²

¹Korea University, Korea

²Chungnam National University, Korea

³Gyeongido Business & Science Accelerator, Korea

⁴Woosuk University, Korea

⁵Korea Institute of Radiological and Biomedical Sciences, Korea

⁶Jeonju University, Korea

We extracted 15 pterosin derivatives from *Pteridium aquilinum* inhibiting β -site amyloid precursor protein cleaving enzyme 1 (BACE1) and cholinesterases involved in the pathogenesis of Alzheimer's disease (AD). (2R)-Pterosin B inhibited BACE1, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC₅₀ of 29.6, 16.2 and 48.1 μ M, respectively. Ki values and binding energies (kcal/ mol) between pterosins and BACE1, AChE and BChE corresponded to the respective IC₅₀ values. (2R)-Pterosin B was a noncompetitive inhibitor against human BACE1 and BChE and a mixed-type inhibitor against AChE, binding to the active sites of corresponding enzymes. Molecular docking simulation

of mixed-type and noncompetitive inhibitors for BACE1, AChE and BChE revealed the novel binding site-directed inhibition of the enzymes by pterosins and structure-activity relationship. (2R)-Pterosin B exhibited a strong BBB permeability with the effective permeability (Pe) of 60.3×10^{-6} cm/s on PAMPA-BBB. (2R)-Pterosin B and (2R,3R)-pterostide C significantly decreased the secretion of A β peptides from neuroblastoma cells overexpressing human β -Amyloid Precursor Protein at 500 μ M. Conclusively, our study suggested that a few pterosins are potential scaffolds for multi-target-directed ligands (MTDLs) for AD therapeutics.

Biography

Gil Hong Park is working in Department of Biochemistry and Molecular Biology, College of Medicine, Korea Molecular Medicine and Nutrition Research Institute, Korea University, Seoul 02841, Korea.

ghpark@korea.ac.kr

Notes: